PURPOSE: First-line chemotherapy (Cx-1) in advanced gastric cancer (AGC) provides survival benefit. However, it is unclear who should proceed to second-line chemotherapy (Cx-2). METHODS: We reviewed patients who received Cx-2 for AGC following progressive disease after Cx-1 from 2000 to 2005 at the National Cancer Center Hospital, Tokyo. To evaluate the prognostic factors in Cx-2, Cox regression multivariate analysis was performed. RESULTS: Of 995 patients who received Cx-1 in this study period, 466 met the eligibility criteria. The median progression-free survival in Cx-1 (PFS-1) was 133 days. The median survival time from the date of starting second-line chemotherapy (MST-2) was 207 days. Multivariate analysis revealed that the factors affecting short survival time in Cx-2 were poor performance status (> or = 2), low serum albumin level (<3.5 mg/dL), elevated C-reactive protein level (> or = 1.0 mg/dL), patients with bone, liver or peritoneal metastasis, and patients without previous gastrectomy (p < 0.01). PFS-1 was an independent prognostic factor for survival (PFS-1 <120, MST-2 133 days, PFS-1 > or = 120, MST-2 258 days, hazard ratio 0.71, 95% confidence interval 0.58-0.86, p < 0.01). The Cx-2 regimen (irinotecan vs. taxane) did not correlate with survival. CONCLUSION: PFS-1 is one of the prognostic factors of Cx-2 in patients with AGC.
PURPOSE: First-line chemotherapy (Cx-1) in advanced gastric cancer (AGC) provides survival benefit. However, it is unclear who should proceed to second-line chemotherapy (Cx-2). METHODS: We reviewed patients who received Cx-2 for AGC following progressive disease after Cx-1 from 2000 to 2005 at the National Cancer Center Hospital, Tokyo. To evaluate the prognostic factors in Cx-2, Cox regression multivariate analysis was performed. RESULTS: Of 995 patients who received Cx-1 in this study period, 466 met the eligibility criteria. The median progression-free survival in Cx-1 (PFS-1) was 133 days. The median survival time from the date of starting second-line chemotherapy (MST-2) was 207 days. Multivariate analysis revealed that the factors affecting short survival time in Cx-2 were poor performance status (> or = 2), low serum albumin level (<3.5 mg/dL), elevated C-reactive protein level (> or = 1.0 mg/dL), patients with bone, liver or peritoneal metastasis, and patients without previous gastrectomy (p < 0.01). PFS-1 was an independent prognostic factor for survival (PFS-1 <120, MST-2 133 days, PFS-1 > or = 120, MST-2 258 days, hazard ratio 0.71, 95% confidence interval 0.58-0.86, p < 0.01). The Cx-2 regimen (irinotecan vs. taxane) did not correlate with survival. CONCLUSION: PFS-1 is one of the prognostic factors of Cx-2 in patients with AGC.
Authors: J Lee; T Lim; J E Uhm; K W Park; S H Park; S C Lee; J O Park; Y S Park; H Y Lim; T S Sohn; J H Noh; J S Heo; C K Park; S Kim; W K Kang Journal: Ann Oncol Date: 2007-02-13 Impact factor: 32.976
Authors: Ian Chau; Andy R Norman; David Cunningham; Justin S Waters; Jacqui Oates; Paul J Ross Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Daniel J Sargent; Claus Henning Köhne; Hanna Kelly Sanoff; Brian M Bot; Matthew T Seymour; Aimery de Gramont; Ranier Porschen; Leonard B Saltz; Philippe Rougier; Christopher Tournigand; Jean-Yves Douillard; Richard J Stephens; Axel Grothey; Richard M Goldberg Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: A Sulkes; J Smyth; C Sessa; L Y Dirix; J B Vermorken; S Kaye; J Wanders; H Franklin; N LeBail; J Verweij Journal: Br J Cancer Date: 1994-08 Impact factor: 7.640
Authors: Hyun Jeong Shim; Ju Young Yun; Jun Eul Hwang; Woo Kyun Bae; Sang Hee Cho; Ik Joo Chung Journal: Gastric Cancer Date: 2011-03-23 Impact factor: 7.370
Authors: Katrine R Schoennemann; Jon K Bjerregaard; Tine P Hansen; Karin De Stricker; Morten F Gjerstorff; Helle A Jensen; Lene W Vestermark; Per Pfeiffer Journal: Gastric Cancer Date: 2011-03-17 Impact factor: 7.370